{
  "id": "245d33acd0f4b764",
  "title": "Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial",
  "description": "Combined hormonal therapy and CDK4/6 inhibition face resistance challenges in endometrial cancer. Here, the authors present a phase 2, one-arm clinical trial, where metformin is combined with letrozole (hormonal therapy) and abemaciclib (a CDK4/6 inhibitor) r\u2026",
  "content": "<li>Green, A. et al. A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer. J. Clin. Oncol.42, 55115511 (2024).\r\nGoogle Scholar\u00a0\r\n</li>\u2026 [+7366 chars]",
  "source": "Nature.com",
  "source_url": "https://www.nature.com/articles/s41467-025-67087-8",
  "published_at": "2025-12-03T00:00:00Z",
  "fetched_at": "2025-12-06T18:33:06.472112+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "search:gene therapy CRISPR trial"
  ],
  "location": null,
  "raw_data": {
    "source": {
      "id": null,
      "name": "Nature.com"
    },
    "author": "Panagiotis A. Konstantinopoulos, Ningxuan Zhou, Richard T. Penson, Tien V. Le, Susana Campos, Carolyn Krasner, Alexi A. Wright, Rebecca Porter, Neil Horowitz, Sara Bouberhan, Joyce F. Liu, Sarah Hindenach, Hannah Sawyer, Lani Koppermann, Martin Hayes, Madeline Polak, Meghan Shea, Page Widick, Su-Chun Cheng, Cesar Castro, Jan H. Beumer, Ursula A. Matulonis, Elizabeth K. Lee",
    "title": "Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial",
    "description": "Combined hormonal therapy and CDK4/6 inhibition face resistance challenges in endometrial cancer. Here, the authors present a phase 2, one-arm clinical trial, where metformin is combined with letrozole (hormonal therapy) and abemaciclib (a CDK4/6 inhibitor) r\u2026",
    "url": "https://www.nature.com/articles/s41467-025-67087-8",
    "urlToImage": null,
    "publishedAt": "2025-12-03T00:00:00Z",
    "content": "<li>Green, A. et al. A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer. J. Clin. Oncol.42, 55115511 (2024).\r\nGoogle Scholar\u00a0\r\n</li>\u2026 [+7366 chars]"
  }
}